Results 11 to 20 of about 354 (138)

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial [PDF]

Nature Communications
Anchored immunotherapy is a novel approach for retaining drugs within the tumour microenvironment. Tolododekin alfa is a first-in-class anchored Interleukin 12 (IL-12) linked to aluminum hydroxide. Safety and biological activity were evaluated in a Phase
Jong Chul Park, Brendan Curti, Marcus Butler, Eric Wehrenberg-Klee, Joseph Elassal, Robert Tighe, Sailaja Battula, Gail Iodice, Howard L. Kaufman, John M. Kirkwood   +9 more
doaj   +2 more sources

Real‐World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations [PDF]

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Purpose A significant proportion of patients with locoregional (stage III) cutaneous melanoma recur despite adjuvant systemic therapy. Staging criteria and surgical nodal management have changed since the trials were completed. Data assessing the effect of systemic therapy compared to surveillance are limited, and factors associated with ...
Derek Effiom, Tyler Aprati, Anastasios Karneris, Aleigha Lawless, Tatyana Sharova, Rebecca Johnson, Alexander Menzies, Georgina Long, Benjamin Park, Seungyeon Jung, Douglas Johnson, David Liu, Xue Bai, Keith Flaherty, Ryan Sullivan, Genevieve M. Boland, Sonia Cohen   +16 more
wiley   +2 more sources

ANKARA’DA ERKEN BİZANS DÖNEMİ MEZAR ALANI KAZISI / EARLY BYZANTINE CEMETERY EXCAVATION IN ANKARA

Selçuk Üniversitesi Edebiyat Fakültesi Dergisi, 2016
Roma Dönemi’nde Galatia Eyaleti’nin başkentliğini yapan Ankyra kentinin anıtsal yapıları ve diğer çarpıcı kalıntıları ile olası nekropol alanları genellikle Ankara’nın Erken Cumhuriyet Dönemi imar faaliyetleri sırasında gerçekleşen hafriyat çalışmaları ...
Mahmut AYDIN, Candemir ZOROĞLU
doaj   +1 more source

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma [PDF]

Frontiers in Oncology, 2023
IntroductionHigh-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents by the U.S. F.D.A. for the treatment of metastatic melanoma. There is limited data using the agents concurrently.
Ann W. Silk, Ann W. Silk, Ann W. Silk, Ann W. Silk, Brendan Curti, Jennifer Bryan, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P. Kane, Phoebe Hannon, Christopher Fountain, Jessica Felcher, Andrew Zloza, Andrew Zloza, Andrew Zloza, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Howard L. Kaufman, Janice M. Mehnert, Janice M. Mehnert, Janice M. Mehnert, David F. McDermott, David F. McDermott   +25 more
doaj   +2 more sources

Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models [PDF]

Journal for ImmunoTherapy of Cancer
Background First-line treatment with pembrolizumab plus chemotherapy in recurrent and metastatic head and neck squamous cell carcinomas (HNSCC) has improved survival.
James W Hodge, Howard Kaufman, Michelle R Padget, Kellsye P Fabian, Sailaja Battula, Wiem Lassoued, Ginette Santiago-Sanchez, Clint Tanner Allen   +7 more
doaj   +2 more sources

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision [PDF]

Journal for ImmunoTherapy of Cancer
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients.
James L Gulley, Deborah Collyar, Pedro J Romero, Christian M Capitini, Leisha A Emens, Avery D Posey, Patrick Hwu, Jennifer A Wargo, Ann W Silk, Ana Carrizosa Anderson   +9 more
doaj   +2 more sources

Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference [PDF]

OncoImmunology
The annual ImmunoRad Conference has established itself as a recurrent occasion to explore the possibility of combining radiation therapy (RT) and immunotherapy (IT) for clinical cancer management.
Fereshteh Talebi, Fabiana Gregucci, Jalal Ahmed, Nir Ben Chetrit, Brian D. Brown, Timothy A. Chan, Dhan Chand, Julie Constanzo, Sandra Demaria, Dmitry I. Gabrilovich, Encouse Golden, Andrew Godkin, Chandan Guha, Gaorav P. Gupta, Aisha Hasan, Fernanda G. Herrera, Howard Kaufman, Donna Li, Alan A. Melcher, Sierra McDonald, Taha Merghoub, Arta M. Monjazeb, Sébastien Paris, Sean Pitroda, Anguraj Sadanandam, Dörthe Schaue, Laura Santambrogio, Phillippe Szapary, Julien Sage, James W. Welsh, Anna Wilkins, Kristina H. Young, Eric Wennerberg, Laurence Zitvogel, Lorenzo Galluzzi, Eric Deutsch, Silvia C. Formenti   +36 more
doaj   +2 more sources

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)

Journal for ImmunoTherapy of Cancer, 2022
The broad activity of agents blocking the programmed cell death protein 1 and its ligand (the PD-(L)1 axis) revolutionized oncology, offering long-term benefit to patients and even curative responses for tumors that were once associated with dismal ...
James L Gulley, James Larkin, Leisha A Emens, Mario Sznol, Madhav Dhodapkar, Daniel S Chen, Roy S Herbst, Tim F Greten, Robert L Ferris, Luca Mazzarella, Paolo A Ascierto, Marc S Ernstoff, Michael B Atkins, Kim A Margolin, Brian I Rini, Michael R Bishop, Suresh S Ramalingam, Meredith M Regan, Rachel W Humphrey   +18 more
doaj   +1 more source

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer

Journal for ImmunoTherapy of Cancer, 2023
Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer ...
Anne Mills, Leisha A Emens, Mary L Disis, Kunle Odunsi, John B Liao, Tyler Curiel, Margaret Gatti-Mays, Amir Jazaeri, Emese Zsiros, Marcus O Butler, Jyoti Bajpai, Katherine C Kurnit, Haider Mahdi, Laura Doherty, Claire F Friedman, Melissa A Geller, Sarah F Adams, Shelley A Dodt, Veena S John   +18 more
doaj   +1 more source

Kościół wobec idolatrii na podstawie dokumentów synodów w latach 50-381

Vox Patrum, 2010
Dieser Aufsatz beschäftigt sich mit dem Thema: Kirche gegen Idolatrie in Acta synodalia in Jahren 50-308. Das Verhältnis der antiken Kirche zum Heidentum wurde schon oft in verschiedenen Publikationen untersucht. Im Rahmen dieses Artikels analisiert der
Michał Kieling
doaj   +1 more source